AUPH - Aurinia Pharma GAAP EPS of -$0.27 in-line revenue of $21.63M beats by $2.39M
Aurinia Pharma press release (NASDAQ:AUPH): Q1 GAAP EPS of -$0.27 in-line. Revenue of $21.63M (+2276.9% Y/Y) beats by $2.39M. The company maintains net revenue guidance range of $115M-$135M from sales of LUPKYNIS for 2022 vs. consensus of $138.01M.
For further details see:
Aurinia Pharma GAAP EPS of -$0.27 in-line, revenue of $21.63M beats by $2.39M